1 domain / 2 areas / 1 specialization
Bail Capital
Data updated
Bail Capital is an early-stage venture firm. Its psychedelic-field connection is participation in Delix Therapeutics’ US$70 million Series A in 2021, backing the developer of non-hallucinogenic “psychoplastogen” small molecules for brain disorders.
Investor Context
Venture CapitalInvestment Context
This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage focus is not listed yet. Psychedelic-market posture: Psychedelic-Adjacent Focus.
Public Portfolio Examples
- Delix TherapeuticsSeries A - $70 million - Sep 27, 2021
Created from documented participation in 1 psychedelic financing round. Profile details beyond documented deals are unverified.
Investor Type
Venture Capital Fund
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Stage focus is not listed yet.
Investment Focus Areas
Focus areas are not listed yet.
Recorded Investments